# Assessment of Efficacy and Safety of Therapy With COVID-19 Convalescent Plasma in Subjects With Severe COVID-19 (IPCO)

> **NCT04712344** · PHASE2 · UNKNOWN · sponsor: **University of Erlangen-Nürnberg Medical School** · enrollment: 58 (estimated)

## Conditions studied

- Severe COVID-19

## Interventions

- **BIOLOGICAL:** COVID-19 convalescent plasma

## Key facts

- **NCT ID:** NCT04712344
- **Lead sponsor:** University of Erlangen-Nürnberg Medical School
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-01-18
- **Primary completion:** 2021-09
- **Final completion:** 2021-09
- **Target enrollment:** 58 (ESTIMATED)
- **Last updated:** 2021-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04712344

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04712344, "Assessment of Efficacy and Safety of Therapy With COVID-19 Convalescent Plasma in Subjects With Severe COVID-19 (IPCO)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04712344. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*